EFFECTOR Therapeutics Shares Are Trading Lower. The Company Announced Topline Results From the Primary Analysis of the Randomized Phase 2 KICKSTART Trial of Tomivosertib Combined With Pembrolizumab in Non-small Cell Lung Cancer
EFFECTOR Therapeutics的股价走低。该公司公布了Tomivosertib与Pembrolizumab联合用于非小细胞肺癌的随机2期KICKSTART试验的初步分析结果